Quintiles to provide drug research unit at Guy's Hospital, London

Published: 28-Oct-2009
Research & Development Pharmaceutical

Integrated biopharmaceutical services company Quintiles has signed a collaborative agreement with Guy\'s and St Thomas\' NHS Foundation Trust and King\'s College London under which Quintiles has commissioned a state-of-the-art research facility with 30 beds, for both patients and healthy volunteers involved in research, at Guy\'s Hospital, London.


Integrated biopharmaceutical services company Quintiles has signed a collaborative agreement with Guy's and St Thomas' NHS Foundation Trust and King's College London under which Quintiles has commissioned a state-of-the-art research facility with 30 beds, for both patients and healthy volunteers involved in research, at Guy's Hospital, London.

The facility, to be completed in early 2010, will be called the Quintiles Drug Research Unit at Guy's Hospital. Quintiles said it would significantly boost its capacity to conduct proof-of-concept programmes that help biopharmaceutical companies develop better medicines faster.

The facility will also bring Quintiles physically and professionally closer to academic and medical colleagues at King's Health Partners'; Academic Health Sciences Centre and its National Institute for Health Research comprehensive Biomedical Research Centre (BRC).

The Quintiles Drug Research Unit at Guy's Hospital will be positioned next to clinical research facilities and a Good Manufacturing Practice (GMP) pharmacy currently being developed by Guy's and St Thomas' and King's College London and adjacent to the BRC's new Faculty of Translational Medicine.

The new unit in Guy's Hospital Tower is an expansion of Quintiles existing facilities in Newcomen Street, London.

Professor Robert Lechler, vice-principal (health) at King's College London and director of King's Health Partners, said: "Through this collaboration and the significant investments we have already made to develop first class clinical research facilities, we will create a powerful "experimental medicine" hub across four floors of the Guy's Hospital Tower, allowing us to harness the expertise of our world class scientists and clinicians to drive new discoveries in medicine and clinical treatment."

See more

You may also like

Regulatory

Quintiles expands Phase I capabilities

Read more
Quintiles opens new unit for patients and healthy volunteers in London, UK.

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  3. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  4. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
  5. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Quintiles expands Phase I capabilities

Quintiles opens new unit for patients and healthy volunteers in London, UK.
Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Anton Paar launches next-generation rheometers for unmatched precision

New instrument series redefines possibilities in rheological testing and analysis
Subscribe now